


# Bisulfite sequencing

# DNA methylation


An epigenetic modification of the DNA sequence: adding a methyl group to the 5 position of cytosine (5mC)



Primarily happens at **CpG sites** (C followed by a G), although non-CG methylation exists

# DNA methylation

In human genome, >90% of CpG sites are fully methylated, except at CpG islands where methylation levels are typically low.



Varley K E et al. *Genome Res.* 2013;23:555-567

Methylation of CpG islands in/near promoter region of gene could silence gene expression.

# Function of DNA methylation

- Important in gene regulation
  - Methylation of promoter regions can suppress gene expression
- Plays crucial role in development
  - Heritable during cell division
  - Helps cells establish identity during cell/tissue differentiation
- Can be influenced by environment
  - Good candidate to mediate GxE interactions

# Sequencing approaches for DNA methylation

- Can be divided into two categories
  - Capture-based or enrichment-based sequencing
    - Use methyl-binding proteins or antibodies to capture methylated DNA fragments, then sequence fragments
    - **Resolution is low**: can typically quantify the amount of DNA methylation in 100-200 bp regions
  - Bisulfite-conversion-based sequencing
    - Bisulfite treatment converts unmethylated C's to T's
    - Sequencing converted data gives **single-bp resolution**
    - Can measure methylation status of each CpG site
    - Until recently, not possible to distinguish 5mC from 5hmC
- Focus of this lecture: **bisulfite sequencing**

# Capture-based sequencing approaches

- All involve capture of methylated DNA followed by sequencing
- MeDIP-seq (Methylated DNA ImmunoPrecipitation)<sup>1</sup>
  - Like ChIP-seq, but uses antibody against methylated DNA
  - MEDIPS<sup>2</sup> is a popular tool for analysis
- Capture via methyl-binding domain proteins: MBD-seq<sup>3</sup>/MIRA-seq<sup>4</sup>, methylCap-seq<sup>5</sup>
- Capture via methyl-sensitive restriction enzymes (MRE-seq)<sup>6</sup>


<sup>1</sup>Weber et al. (2005) *Nat Genet*; <sup>2</sup>Chavez et al. (2010) *Gen Res*; <sup>3</sup>Serre et al. (2010) *NAR*

<sup>4</sup>Rauch et al. (2010) *Methods*; <sup>5</sup>Brinkman et al. (2010) *Methods*; <sup>6</sup>Maunakea et al. (2010) *Nature*

# Bisulfite sequencing (BS-seq)

- Technology in a nutshell:
  - Treat fragmented DNA with bisulfite
    - Unmethylated C will be converted to U, amplified as T
    - Methylated C will be protected and remain C
    - No change for other bases
  - Amplify the treated DNA
  - Sequence the DNA segments

# Reduced representation bisulfite sequencing (RRBS)<sup>1,2</sup>

- Goal: affordable alternative to genome-wide sequencing
  - By narrowing focus to CpG-rich areas, reduce # of reads necessary to obtain deep coverage of promoter regions
  - Interrogates ~1% of the genome but 5-10% of CpG sites
- Approach: enrich for CpG-rich segments of genome
  - MspI restriction enzyme cuts at CpG sites, leaving fragments with CpGs at either end:  
  
either end: CCGG  
                  CCGG
  - Size selection for fragments of 40-220bp maximizes coverage of promoter regions and CpG islands
  - Bisulfite treat, amplify, end-sequence, and align fragments to genome

<sup>1</sup>Meissner (2005) *NAR*; <sup>2</sup>Gu et al. (2011) *Nat Protoc*

# Illustration of bisulfite conversion

Watson >>**AC<sup>m</sup>GTT**CGCTTGAG****>>

Crick <<**TG**C<sup>m</sup>AAG**CGAACTC******<<

**C<sup>m</sup>** methylated

**C** Un-methylated

1) Denaturation



Watson >>**AC<sup>m</sup>GTT**CGCTTGAG****>>

Crick <<**TG**C<sup>m</sup>AAG**CGAACTC******<<

2) Bisulfite Treatment



BSW >>**AC<sup>m</sup>GTT**UGUTT**GAG**>>

BSC <<**TG**C<sup>m</sup>AAG**UGAAUTU******<<

3) PCR Amplification



BSW >>**AC<sup>m</sup>GTT**TGTTT**GAG**>>

BSC <<**TG**C<sup>m</sup>AAG**TGAATT******<<

BSWR <<**TG**CAA**CAAACTC******<<

BSCR >>**AC**G** TTC**ACTTAA****>>

# Alignment of BS-seq


- Problem: reads cannot be directly aligned to the reference genome.
  - Four different strands after bisulfite treatment and PCR
  - C-T mismatches: unmethylated reads can't be aligned to the correct position
    - Unmethylated CpGs will align with TpGs or likely not at all
    - Will lead to a strong bias in favor of methylated reads
- One possible solution: *in silico* bisulfite conversion
  - Switch all C's to T's in both reads and reference sample
  - Use this for alignment, then change back to original

# Strategy used by BISMAR<sup>1</sup>

- *In silico* bisulfite conversion of fragments **and** reference genome

- Convert all C's to T's
- Make complementary strand by converting all G's to A's
- Align both strands to the four possible reference genomes
- Choose best alignment


- Once aligned, convert back to original bases
- Compare to ref. genome to assess methylation



<sup>1</sup>Krueger and Andrews (2011) *Bioinformatics*

# Alignment issues

- Possible problems with *in silico* approach
  - By converting all C's to T's, reduce sequence complexity to 3 bases
  - Larger search space for possible alignments
  - Could lead to mismatches or non-unique mapping



# Strategy used by BSMAP<sup>1</sup>

- Consider methylation status during alignment
  - create multiple versions of reference seed with C's converted to T's
  - compare each read to all possible seeds
  - do the same for complementary strand
- This approach reduces search space compared to *in silico* conversion of all C's to T's
  - T's in reads can match to C's or T's in reference
  - C's in reads can only match to C's in reference
- Computationally more intensive

**Reference**

>> **ACGTCGCT** TGATAGCT >>

Coordinate: 4875362

**Seed Table**



key

value

original seed

bisulfite seeds

<b>ACGTCGCT</b>	⇒	4875362, ...
<b>ACGTCGTT</b>	⇒	4875362, ...
<b>ACGTTGCT</b>	⇒	4875362, ...
<b>ACGTTGTT</b>	⇒	4875362, ...
<b>ATGTCGCT</b>	⇒	4875362, ...
<b>ATGTCGTT</b>	⇒	4875362, ...
<b>ATGTTGCT</b>	⇒	4875362, ...
<b>ATGTTGTT</b>	⇒	4875362, ...

**Read** >> **ATGTCGCT** TGAGAGCT >>

# Which alignment software is best?

- Advantages of BSMAP:
  - reduces search space by eliminating mapping of C's to T's
  - greater proportion of uniquely mapping reads<sup>1</sup>
- Advantages of BISMARX:
  - much faster than BSMAP and other programs<sup>1</sup>
  - uniqueness of mapping independent of methylation status<sup>1</sup>
  - more user-friendly in terms of extracting data, interfacing with other software<sup>1</sup>
- In general, BISMARX seems to be the popular choice

<sup>1</sup>Chatterjee et al. (2012) *NAR*


# Other aligners

- Alignment of RRBS data
  - Chatterjee et al. notes it is much faster if we use information on MspI cutpoints to “reduce” reference genome *in silico*<sup>1</sup>
  - RRBSMAP: a version of BSMAP that does exactly that<sup>2</sup>
  - Has option to work with different restriction enzymes
- Many other aligners for bisulfite sequencing data
  - One useful review of these is Hackenberg et al.<sup>3</sup>

<sup>1</sup>Chatterjee et al. (2012) *NAR*; <sup>2</sup>Xi et al. (2012) *Bioinformatics*;

<sup>3</sup>Hackenberg et al. (2012): Chapter 2 in “DNA Methylation – From Genomics to Technology” Tatarinova (Ed.) <http://www.intechopen.com/books>

# BS-seq data after alignment



Methylated counts (X)	1	2	1	2	0
Coverage (N)	1	4	2	3	2
Methylation level (X/N)	1	0.5	0.5	0.67	0

**WGBS data**

# BS-seq data

- At each position, we have the total number of reads, and the methylated number of reads:

Position of CpG site		Total # reads	# methylated reads
chr1	3010874	22	18
chr1	3010894	31	27
chr1	3010922	12	10
chr1	3010957	7	6
chr1	3010971	6	6
chr1	3011025	7	5

# Study design for BS-seq studies

- High costs → few samples
- Two common study designs
  - Analysis of a single sample:
    - Goal: observe methylation patterns across genome
    - Commonly done to **characterize methylome** for a particular cell type or species
  - Comparison of several samples:
    - Typical goal: compare methylation among groups:  
**Differential methylation analysis**

# Differential methylation analysis

- Typical goal: compare methylation levels between two groups
  - Example: tumor vs. normal tissue samples
  - Important: do groups contain biological replicates?
  - Some studies may compare 1 tumor to 1 normal sample
  - Other studies will include 2 or more replicates of each
- Popular *ad hoc* approaches for this comparison are Fisher's exact test and two-group t-test
  - We will show why these can be problematic

# Fisher's exact test

- If we have only one sample per group (no biological replicates), Fisher's exact test is a natural choice
- Example: from one CpG site
  - For tumor sample, 32/44 methylated reads
  - For normal sample, 8/12 methylated reads
- Can then perform Fisher's exact test on the following table:

- $OR = 1.33$

- $p = .73$

	Methylated	Unmeth.	Total reads
Tumor	32	12	44
Normal	8	4	12
Total	40	16	56

# Fisher's exact test in methylKit

- For comparisons between two samples, Fisher's exact test is a reasonable choice
  - Easy to carry out in R using `fisher.test()` function
  - Alternatively, methylKit<sup>1</sup> is a suite of R functions that facilitates analysis of genome-wide methylation data
  - Differential methylation analysis via either
    - Fisher's exact test (for comparisons between two samples)
    - Logistic regression based on methylation proportions
      - Analogous to two-group t-test, but with covariates
    - Can perform analysis in user-defined tiling windows
      - However, based on simple collapsing of information across sites rather than smoothing

<sup>1</sup>Akalin *et al.* 2012 **Genome Biology**

# Fisher's exact test with replicates

- For Fisher's exact test with biological replicates, need to collapse read information within groups
- Example: single CpG site sequenced for 4 samples
  - For 2 tumor samples, 32/44 and 4/10 methylated reads
  - For 2 normal samples, 8/12 and 12/34 methylated reads
- Could then perform Fisher's exact test on the following table:

- OR = 2.6
- $p = .0264$

	Methylated	Unmeth.	Total reads
Tumor	36 = 32+4	18	54 = 44+10
Normal	20 = 8+12	26	46 = 12+34
Total	56	44	100

# Problem with Fisher's exact test

- To perform Fisher's exact test with replicates, we have to collapse read counts across samples within each group
- By doing this, we are ignoring information on biological variation between samples
  - **Biological variation:** natural variation in underlying fraction of DNA methylated between samples in the same condition
  - **Technical variation:** variation in estimation of methylation levels due to random sampling of DNA during sequencing<sup>1</sup>
- By collapsing, we are assuming that:
  - samples within a group inherently have the same underlying fraction of DNA methylated
  - any variation between samples is due to technical variation

<sup>1</sup>Hansen *et al.* 2012 *Genome Biology*

# Naïve t-test

- Example: single CpG site sequenced for 4 samples
  - For 2 tumor samples, 32/44 and 4/10 methylated reads
  - For 2 normal samples, 8/12 and 12/34 methylated reads
- For t-test, compute a proportion for each sample
  - .727 and .400 for tumor samples
  - .667 and .353 for normal samples
- Difference in mean proportions =  $.563 - .510 = .053$
- T-statistic = 0.2375
- $p = .834$

# Problem with t-test

- To perform t-test, computed a proportion for each sample
  - Test inherently gives equal weight to each sample
  - Does not account for uncertainty in proportion estimates. Note: such uncertainty is lower for samples with more reads
- Another issue with this approach is the small number of samples
  - With  $N=4$ , the t-test has very little power due to low df

# Fisher's exact vs. t-test

- The two tests yielded very different results
  - Fisher's exact  $p = .0264$
  - T-test  $p = .834$
- Main difference: unit of observation (reads vs. samples)
- Fisher's test was based on 100 "independent" reads
  - Reads are not independent: correlated within each sample, since samples have different methylation fractions
- T-test was based on 4 samples
  - Treated samples as equally informative, when they are not
  - For 2 tumor samples, **32/44** and 4/10 methylated reads
  - For 2 normal samples, 8/12 and **12/34** methylated reads

# Need better approaches


- Problem: want to test many sites with few samples
  - Limited information available at each site due to low # of samples
- Solution: borrow information across CpG sites
  - Smoothing approaches that share information across nearby sites
  - Bayesian hierarchical model that borrows information across the genome

# Smoothing approaches

- First consider **analysis of a single sample**
- Goal here is to identify methylated regions:
  - Can estimate proportion of reads that are methylated at each C position, but:
    - Variability in estimation needs to be considered
    - Spatial correlation among nearby CpG sites can be utilized to improve estimation
  - Methylated regions (or states) can be determined by smoothing based methods using the estimated methylation proportion as input

# HMM: Hidden Markov model

- Model switches between states along a chromosome
- Could model 3 methylation states: FMR, LMR, UMR
  - Stadler et al.<sup>1</sup> used estimated proportions to identify regions in mouse methylome corresponding to 3 states



# Smoothing sequencing data

- Problem with directly smoothing the proportions:
  - Doesn't consider the uncertainty in proportion estimates: estimates are more variable for sites with low coverage
  - May want to put less weight on these estimates
- A better approach: BSmooth model<sup>1</sup>
  - A local-likelihood smoothing approach
  - Key assumptions:
    - True methylation level  $\pi_j$  is a smooth curve of genomic coordinates.
    - The observed counts  $M_j$  follow a binomial( $N_j, \pi_j$ ) distribution.
    - Binomial assumption accounts for differences in variation for samples with different total read counts  $N_j$

# BSmooth smoothing

- Notation for CpG site  $j$ :
  - $N_j, M_j$ : # total and # methylated reads
  - $\pi_j$ : underlying true methylation level
  - $l_j$ : location
- Model:  $M_j \sim \text{Bin}(N_j, \pi_j)$ 
$$\log(\pi_j / (1 - \pi_j)) = \beta_0 + \beta_1 l_j + \beta_2 l_j^2$$
where  $\beta_0, \beta_1, \beta_2$  vary smoothly along the genome.
- Fit this as a weighted generalized linear model (GLM)
- Obtain a smoothed methylation estimate for each position along the genome using sliding window

# Sliding window approach

- Choose window size (either distance or # CpG sites)
- For every genomic location  $l_j$ , use data in window surrounding  $l_j$
- Fit weighted GLM for all data in window, where weight for data point  $k$  depends inversely on:
  - the variance of estimated  $\pi_k$ , estimated as  $\pi_k(1-\pi_k)/N_k$
  - distance of CpG site from window center  $|l_k - l_j|$
- Estimation of  $\beta_0, \beta_1, \beta_2$  in window surrounding  $l_j$  provides estimate of  $\pi_j$

# Benefits of smoothing dense data

- By borrowing information across sites, can achieve high precision even with low coverage
  - Pink line is from smoothing full 30x data
  - Black line is from smoothing 5x version of data
  - Correlation = .90 across entire dataset
  - Median absolute difference of .056



# Smoothed differential methylation analysis

- Goal: identify regions **differentially methylated** (DMRs) between groups
- BSmooth computes a t-test-like statistic
  - Signal-to-noise ratio based on smoothed data for multiple samples
  - Essentially the average difference between smoothed profiles from 2 groups, divided by estimated standard error
  - When biological replicates are included, this statistic correctly accounts for biological variation
- Identify DMRs as regions where this statistic exceeds some cutoff

# Bsmooth functions implemented in Bioconductor package bsseq<sup>1</sup>

- Functions for
  - Smoothing
  - Smoothed t-tests
  - DMR identification
  - Visualization of results
  - Fisher's exact test (not smoothed)
- Can be implemented in parallel computing environment to speed up calculation

# Use bsseq

- First create BSseq objects
- Use BSmooth function to smooth.
- `fisherTests` performs Fisher's exact test, if there's no replicate.
- `BSmooth.tstat` performs t-test with replicates.
- `dmrFinder` calls DMRs based on `BSmooth.tstat` results.

```
library(bsseq)
library(bsseqData)

## take chr21 on BS.cancer.ex to speed up calculation
data(BS.cancer.ex)
ix = which(seqnames(BS.cancer.ex)=="chr21")
BS.chr21 = BS.cancer.ex[ix,]

## use BSmooth to smooth and call DMR
BS.chr21 = BSmooth(BS.chr21) ## this takes 1-2 minutes

## perform t-test
BS.chr21.tstat = BSmooth.tstat(BS.chr21,
    c("C1", "C2", "C3"), c("N1", "N2", "N3"))

## call DMR
dmr.BSmooth <- dmrFinder(BS.chr21.tstat, cutoff = c(-4.6, 4.6))
```

# Another approach: Bayesian hierarchical model<sup>1</sup>

- Hierarchical model to separately model biological and technical variation
  - **Biological variation:** natural variation in underlying fraction of DNA methylated between samples in the same condition
  - **Technical variation:** variation in estimation of methylation levels
  - Many methods only capture one or the other
    - Fisher's exact test: technical variation only
    - Naïve t-test: biological variation only
- Shrinkage approach allows us to borrow information across genome
  - useful when information per CpG site is limited due to low number of samples


# Beta-binomial hierarchical model

- “The most natural statistical model for replicated BS-seq DNA methylation measurements”<sup>1</sup>
- Sampling of reads for each CpG site will follow a binomial distribution
  - Out of  $N$  reads covering a particular site, how many are methylated?
  - This number will follow a binomial( $N, \pi$ ) distribution
  - However,  $\pi$  may vary across replicates
- To model the biological variation of  $\pi$  across replicates, the beta distribution is a natural choice
- Beta-binomial distribution used to model methylated reads in DSS<sup>2</sup>, BiSeq<sup>3</sup>, MOABS<sup>4</sup>, RADMeth<sup>5</sup>, MethylSig<sup>6</sup>

<sup>1</sup>Robinson et al. 2014; <sup>2</sup>Feng et al. 2014; <sup>3</sup>Hebestreit et al. 2013; <sup>4</sup>Sun et al. 2014;  
<sup>5</sup>Dolzhenko & Smith 2014; <sup>6</sup>Park et al. 2014

# Beta-binomial hierarchical model

- Example: CpG site  $i$ , two groups  $j=1$  (cancer) and 2 (normal), two replicates per group ( $k = 1, 2$ )




- **Biological variation** modeled by dispersion parameter  $\phi_{ij}$ 
  - Replicates in each group may vary in true methylation proportion  $\pi_{ijk}$
- **Technical variation:** given  $N_{ijk}$  and  $\pi_{ijk}$ , number of methylated reads  $M_{ijk}$  varies due to random sampling of DNA
- **Goal:** test whether  $\mu_{i1}$  and  $\mu_{i2}$  are significantly different

# Motivation for shrinkage approach

- Hierarchical model:  $M_{ijk} \sim \text{Binomial}(N_{ijk}, \pi_{ijk})$   
 $\pi_{ijk} \sim \text{Beta}(\mu_{ij}, \phi_{ij})$
- **Goal: after correctly modeling different sources of variation, test whether  $\mu_{i1}$  and  $\mu_{i2}$  are significantly different at CpG  $i$**
- Possible limitation of model: with small number of samples, estimation of parameters may be poor
- Solution: borrow information from CpG sites across the genome to obtain reasonable estimates of  $\phi_{ij}$

# Estimating dispersion parameter

- To obtain stable estimates of dispersion with few samples, we:
  - impose a log-normal prior on  $\phi$ :  $\phi_{ij} \sim \text{log normal}(m_j, r_j^2)$
  - use information from all CpGs in the genome to estimate the parameters  $m_j$  and  $r_j^2$
- Choice of log-normal prior was motivated by distribution of dispersion in bisulfite sequencing data
  - Estimation robust to departure from log-normality
  - Prior provides a good “referee”
  - Encourages dispersion estimates to stay within bounds



# Wald test for DML, based on hierarchical model<sup>1</sup>

- DML: Differentially Methylated Loci
  - Test for differential methylation at each CpG site
- At site  $i$ , test:  $H_0 : \mu_{i1} = \mu_{i2}$
- Basic algorithm:
  - Use naïve estimates of  $\phi$  across genome to estimate prior
  - For each site  $i$ , estimate  $\mu_{i1}$  and  $\mu_{i2}$  as proportion of methylated reads for each group
  - Bayesian estimation of  $\phi_{ij}$  based on data and prior
  - Plug in estimates of  $\mu_{ij}$  and  $\phi_{ij}$  to create Wald statistic of

form 
$$t_i = \frac{\hat{\mu}_{i1} - \hat{\mu}_{i2}}{\sqrt{\text{Var}(\hat{\mu}_{i1} - \hat{\mu}_{i2})}}$$

# Using DSS to call DML and DMRs

- DSS can identify differentially methylated *loci* (DML) and *regions* (DMRs)
  - DML identified via Wald test, based on p-value threshold
  - DMRs called from DML based on user-specified criteria (region length, p-value and effect size thresholds)
  - Accommodates single-replicate studies by smoothing data from nearby CpG sites to form “pseudo-replicates”<sup>1</sup>
  - Inclusion of design matrix to allow covariates and a more general experimental design<sup>2</sup>

<sup>1</sup>Wu et al. *Nucleic Acids Research* 2015.

<sup>2</sup>Park et al. *Bioinformatics* 2016.

# BS-seq experiment under general design

- General experimental design:
  - Multiple groups.
  - Multiple factors, crossed/nested.
  - Continuous covariates.
- Limited data analysis methods with not so good properties:
  - BiSeq and RADMeth, both based on generalized linear model (GLM).
  - Computationally demanding.
  - Numerically unstable.

# DSS-general

- Suppose the input data include  $N$  CpG sites and  $D$  samples.
- Notations:
  - $Y_{id}, m_{id}$ : methylated and total counts for  $i^{\text{th}}$  CpG and  $d^{\text{th}}$  data set.
  - $\pi_{id}, \Phi_i$ : mean and dispersion.
  - $\mathbf{X}$ : full ranked design matrix of dimension  $D$  by  $p$ .
- Counts are modeled by a beta-binomial regression:
$$Y_{id} \sim \text{beta-bin}(m_{id}, \pi_{id}, \phi_i)$$
$$g(\pi_{id}) = \mathbf{x}_d \boldsymbol{\beta}_i$$
- DML detection is achieved by a general hypothesis testing:
$$H_0 : \mathbf{C}^T \boldsymbol{\beta}_i = 0, \text{ where } \mathbf{C} \text{ is a } p\text{-vector.}$$

# GLM approximation

- Beta-binomial regression.
- Transformation:
  - $g(Y/m)$  as response or data
  - What is  $g(\cdot)$ ?
- Applying generalized (weighted) least square to estimate parameters, but with caution!

# Choice of the link function

- arcsine link:  $g(x) = \arcsin(2x - 1)$
- “Variance stabilization transformation” for binomial proportion:
  - Variance of the transformed data does not depend on mean (but on dispersion), so least square approach is possible.
    - Note: logit or probit transformed data needs iterative procedure since variance depends on mean.
  - More linear than logit or probit, especially at the boundaries.

# Parameter estimation

- Model:  $Y_{id} \sim \text{beta-bin}(m_{id}, \pi_{id}, \phi_i)$   
 $g(\pi_{id}) = \mathbf{x}_d \boldsymbol{\beta}_i$

- Transformation:

$$Z_{id} = \arcsin(2Y_{id}/m_{id} - 1).$$

$$E[Z_{id}] \approx \arcsin(2E[Y_{id}]/m_{id} - 1) = \arcsin(2\pi_{id} - 1) = \mathbf{x}_d \boldsymbol{\beta}_i$$

$$\text{var}(Z_{id}) \approx \frac{1 + (m_{id} - 1)\phi_i}{m_{id}}.$$

$$V_i = \text{diag} \left( \frac{1 + (m_{id} - 1)\phi_i}{m_{id}} \right)$$

- Least square estimator:

$$\hat{\boldsymbol{\beta}}_i = (\mathbf{X}^T V_i^{-1} \mathbf{X})^{-1} \mathbf{X}^T V_i^{-1} \mathbf{Z}.$$

# Two-step estimation

- Dispersion estimation

- Estimate  $\hat{\beta}_i^{(0)}$  by setting dispersion to 0.

- Estimate variance based on Pearson's chi-square statistics:

$$\chi_i^2 = \sum_d m_{id} (Z_{id} - \mathbf{x}_d \hat{\beta}_i^0)^2, \quad \hat{\sigma}_i^2 = \chi_i^2 / (D - p),$$

- Dispersion can be derived as:

$$\hat{\phi}_i = \frac{D(\hat{\sigma}_i^2 - 1)}{\sum_d (m_{id} - 1)}.$$

- Restriction:  $1 < \hat{\sigma}_i^2 < \frac{\sum_d (m_{id} - 1)}{D} + 1$ .

- Parameter estimation using GLS based on  $\hat{\phi}_i$

# Hypothesis testing

- For testing
  - Variance/covariance matrix estimates:

$$\hat{\Sigma}_i \equiv \widehat{\text{var}}(\hat{\beta}_i) = (\mathbf{X}^T \hat{V}_i^{-1} \mathbf{X})^{-1}.$$

- Wald test statistics for  $H_0 : C^T \beta_i = 0$ ,

$$t_i = \frac{C^T \hat{\beta}_i}{\sqrt{C^T \hat{\Sigma}_i C}}$$

# Use DSS

- Input data object has the same format as `bsseq`.
- `DMLtest` performs Wald test at each CpG.
- `callDML/callDMR` calls DML or DMR.

```
## two group comparison
```

```
dmlTest <- DMLtest(BSobj, group1=c("C1", "C2", "C3"),  
                  group2=c("N1", "N2", "N3"),  
                  smoothing=TRUE, smoothing.span=500)
```

```
dmrs <- callDMR(dmlTest)
```

```
## A 2x2 design
```

```
DMLfit = DMLfit.multiFactor(RRBS, design, ~case+cell)
```

```
DMLtest = DMLtest.multiFactor(DMLfit, term="case")
```

# Conclusions

- Analysis of genome-wide bisulfite sequencing data presents some unique challenges
  - Alignment of reads can be complicated
  - Many tests to be performed, but number of samples sequenced is limited by costs in most experiments
  - Beta-binomial model is widely used.

# References

## For software/analysis

- Akalin *et al.* 2012 *Genome Biology* 13:R87. **MethylKit** paper.
- Chatterjee *et al.* (2012) *Nucleic Acids Research*. 40(10):e79. **Compares aligners.**
- Chavez *et al.* (2010) *Genome Research* 20:1441-50. **MEDIPS** software.
- Dolzhenko and Smith (2014) *BMC Bioinformatics* 15:215. **RADMeth.**
- Feng, Conneely, and Wu (2014) *Nucleic Acids Research* 42(8):e69, **DSS for two-group.**
- Hansen *et al.* (2012) *Genome Biology* 13:R83. **Bsmooth** paper.
- Hebestreit, Dugas, and Klein (2013) *Bioinformatics* 29:1647-53. **BiSeq.**
- Krueger and Andrews (2011) *Bioinformatics* 27(11):1571-2. **BISMAR**K aligner.
- Park *et al.* (2014) *Bioinformatics* 30:2414-22. **MethylSig.**
- Robinson *et al.* (2014) *Frontiers in Genetics* 5:324. **Review of methods for DML and DMR**
- Stadler *et al.* (2012) *Nature* 480:490-6. **Mouse methylome paper that used HMM.**
- Sun *et al.* (2014) *Genome Biology* 15:R38. **MOABS.**
- Wu *et al.* (2015) *Nucleic Acids Research*. 43(21):e141. **DSS-single for single replicates.**
- Park and Wu (2016) *Bioinformatics* 32 (10), 1446-1453. **DSS-general for general design.**
- Xi and Li (2009) *BMC Bioinformatics* 10:232. **BSMAP** aligner.
- Xi *et al.* (2012) *Bioinformatics* 28(3):430-2. **RRBSMAP** aligner.

# References

## For different sequencing technologies

- Bock et al. (2010) *Nat Biotech* 28(10):1106-16. **Compares RRBS, MeDIP-seq, others**
- Brinkman et al. (2010) *Methods* 52:232-236. **MethylCap-seq.**
- Gu et al. (2011) *Nat Protoc* 6(4):468-81. **Genome-wide RRBS protocol.**
- Maunakea et al. (2010) *Nature* 466:253-7. **MRE-seq.**
- Meissner (2005) *Nucleic Acids Research*. 33:5868-77. **Original RRBS paper.**
- Rauch et al. (2010) *Methods* 52:213-7. **MIRA-seq.**
- Serre et al. (2010) *Nucleic Acids Research*. 38:391-9. **MBD-seq.**
- Weber et al. (2005) *Nat Genet* 37:853-62. **Original MeDIP paper.**